Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4178-4186

  Van Der Kwast, Theodorus H ^a   Bolla, Michel ^b   Van Poppel, Hein ^b   Van Cangh, Paul ^b   Vekemans, Kris ^b   Da Pozzo, Luigi ^b   Bosset, Jean Francois ^b   Kurth, Karl H ^b   Schröder, Fritz H ^b   Collette, Laurence ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION HAZARD; RANDOMIZATION; RISK FACTOR; STATISTICAL SIGNIFICANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; EUROPE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

PROSTATE SPECIFIC ANTIGEN;

AGED; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 34948825892     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.4067     Document Type: Article

References (41)

1. Amling CL, Blute ML, Bergstralh EJ, et al: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol 164:101-105, 2000
2. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001
3. Hull GW, Rabbani F, Abbas F, et al: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167:528-534, 2002
4. Wheeler TM, Dillioglugil O, Kattan MW, et al: Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 29:856-862,1998
5. Swindle P, Eastham JA, Ohori M, et al: Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 174:903-907, 2005
6. Anscher MS, Prosnitz LR: Multivariate analysis of factors predicting local relapse after radical prostatectomy-possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys 21:941-947, 1991
7. Perez CA, Beyer DC, Blasko JC, et al: Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate: American College of Radiology. ACR Appropriateness Criteria. Radiology 215:1449-1472, 2000 (suppl)
8. Valicenti RK, Chervoneva I, Gomella LG: Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 58:1093-1097, 2004
9. Teh BS, Bastasch MD, Mai WY, et al: Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins. J Urol 175:2097-2101, 2006
10. Bolla M, van Poppel H, Collette L, et al: Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet 366:572-578, 2005
11. Collette L, van Poppel H, Bolla M, et al: Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer 41:2662-2672, 2005
12. van der Kwast TH, Collette L, Van Poppel H, et al: Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch 449:428-434, 2006
13. Stamey TA, McNeal JE, Freiha FS, et al: Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 139:1235-1241, 1988
14. Montironi R, Van der Kwast T, Boccon-Gibod L, et al: Handling and pathology reporting of radical prostatectomy specimens. Eur Urol 44:626-636, 2003
15. Kalbfleisch JD, Prentice RL: Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, pp 163-178
16. Early Breast Cancer Trialists' Collaborative Group.Treatment of Early Breast Cancer: Vol 1. Worldwide Evidence 1985-1990. Oxford, United Kingdom, Oxford University Press, 1990
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Gerber GS, Thisted RA, Scardino PT, et al: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276:615-619, 1996
19. Porter CR, Kodama K, Gibbons RP, et al: 25-year prostate cancer control and survival outcomes: A 40-year radical prostatectomy single institution series. J Urol 176:569-574, 2006
20. Khan MA, Partin AW: Surgical margin status after radical retropubic prostatectomy. BJU Int 95:281-284, 2005
21. Vis AN, Schroder FH, van der Kwast TH: The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 50:258-265, 2006
22. Han M, Partin AW, Chan DY, et al: An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 171:23-26, 2004
23. Reference deleted.
24. D'Amico AV, Whittington R, Malkowicz SB, et al: Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer 88:2110-2115, 2000
25. Anscher MS: Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int J Cancer 96:91-93, 2001
26. Choo R, Hruby G, Hong J, et al: Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: To irradiate or not? Int J Radiat Oncol Biol Phys 52:674-680, 2002
27. Gomella LG, Zeltser I, Valicenti RK: Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology 62:46-54, 2003 (suppl 1)
28. Vargas C, Kestin LL, Weed DW, et al: Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 61:714-724, 2005
29. Epstein JI, Amin M, Boccon-Gibod L, et al: Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol 216:34-63, 2005 (suppl)
30. Kamat AM, Babaian K, Cheung MR, et al: Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 170:1860-1863, 2003
31. de la Taille A, Flam TA, Thiounn N, et al: Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int 90:887-892, 2002
32. Cadeddu JA, Partin AW, DeWeese TL, et al: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159:173-177, 1998
33. Lee HM, Solan MJ, Lupinacci P, et al: Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): Effect of adjuvant radiotherapy. Urology 64:84-89, 2004
34. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
35. Jhaveri FM, Zippe CD, Klein EA, et al: Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-years results. Urology 54:884-890, 1999
36. Collette L, Burzykowski T, Schroder FH: Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 42:1344-1350, 2006
37. Ohori M, Abbas F, Wheeler TM, et al: Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol 161:500-504, 1999
38. Fesseha T, Sakr W, Grignon D, et al: Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol 158:2176-2179, 1997
39. Watson RB, Civantos F, Soloway MS: Positive surgical margins with radical prostatectomy: Detailed pathological analysis and prognosis. Urology 48:80-90, 1996
40. Pettus JA, Weight CJ, Thompson CJ, et al: Biochemical failure in men following radical retropubic prostatectomy: Impact of surgical margin status and location. J Urol 172:129-132, 2004
41. Palisaar RJ, Graefen M, Karakiewicz PI, et al: Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol 41:155-161, 2002